A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they live ...

When an HIV Scientific Breakthrough Isn’t Enough Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.

Lower-income countries, including South Africa, gain unprecedented access to lenacapavir, a revolutionary HIV prevention drug ...

The UNAIDS annual report warns that Trump era HIV funding cuts could lead to 6 million more infections and 4 million deaths ...

HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

HIV jab has signed a deal to supply the costly injection at a knock-down price to as many as two million people in poorer countries.

Africa Check has debunked viral social media claims about an HIV “cure”, clarifying that the breakthrough is promising, but not a cure or vaccine.

A new report says the withdrawal of U.S. funding has caused a “systemic shock” to the global effort against AIDS and HIV.

Gilead’s daily antiviral pills can prevent HIV transmission and slow AIDS. While an HIV vaccine remains the Holy Grail, Gilead’s new long-lasting injection, lenacapavir, is the next best thing.